

Alfredo Alberti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2359109/publications.pdf>

Version: 2024-02-01

290
papers

17,739
citations

17405

63
h-index

16127

124
g-index

293
all docs

293
docs citations

293
times ranked

10299
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-invasive evaluation of liver fibrosis using transient elastography. <i>Journal of Hepatology</i> , 2008, 48, 835-847.	1.8	1,170
2	A proposed system for the nomenclature of hepatitis C viral genotypes. <i>Hepatology</i> , 1994, 19, 1321-1324.	3.6	962
3	Global Burden of Disease (GBD) for Hepatitis C. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 20-29.	1.0	429
4	Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. <i>Lancet, The</i> , 1992, 340, 697-698.	6.3	401
5	Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. <i>Gut</i> , 2004, 53, 744-749.	6.1	391
6	Natural history and prognostic factors for chronic hepatitis type B.. <i>Gut</i> , 1991, 32, 294-298.	6.1	362
7	SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2005, 42, 615-624.	1.8	357
8	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011, 31, 30-60.	1.9	333
9	Natural history of hepatitis C. <i>Journal of Hepatology</i> , 1999, 31, 17-24.	1.8	328
10	Antibodies to the Surface of Halothane-Altered Rabbit Hepatocytes in Patients with Severe Halothane-Associated Hepatitis. <i>New England Journal of Medicine</i> , 1980, 303, 66-71.	13.9	303
11	Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. <i>Cancer</i> , 1994, 74, 2442-2448.	2.0	294
12	Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. <i>Hepatology</i> , 1986, 6, 167-171.	3.6	278
13	HCV-associated liver cancer without cirrhosis. <i>Lancet, The</i> , 1995, 345, 413-415.	6.3	276
14	Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. <i>Journal of Hepatology</i> , 1992, 16, 273-281.	1.8	259
15	Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2006, 44, 686-693.	1.8	247
16	Clinical and virological profiles in patients with multiple hepatitis virus infections. <i>Gastroenterology</i> , 1993, 105, 1529-1533.	0.6	233
17	Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. <i>World Journal of Gastroenterology</i> , 2006, 12, 3682.	1.4	220
18	Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. <i>Journal of Hepatology</i> , 1997, 26, 961-966.	1.8	219

#	ARTICLE	IF	CITATIONS
19	Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. <i>Nature</i> , 1990, 345, 258-260.	13.7	208
20	Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. <i>Hepatology</i> , 2004, 39, 333-342.	3.6	198
21	High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. <i>Gastroenterology</i> , 1992, 102, 956-962.	0.6	193
22	Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2010, 52, 191-198.	1.8	188
23	Liver Microsomal Triglyceride Transfer Protein Is Involved in Hepatitis C Liver Steatosis. <i>Gastroenterology</i> , 2006, 130, 1661-1669.	0.6	187
24	Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis.. <i>Gut</i> , 1982, 23, 270-275.	6.1	186
25	Influence of Hepatitis Delta Virus Infection on Progression to Cirrhosis in Chronic Hepatitis Type B. <i>Journal of Infectious Diseases</i> , 1987, 155, 931-935.	1.9	184
26	Management of hepatitis C. <i>Journal of Hepatology</i> , 2003, 38, 104-118.	1.8	176
27	Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. <i>Hepatology</i> , 1995, 22, 700-706.	3.6	175
28	Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study. <i>Hepatology</i> , 2002, 36, 973-977.	3.6	163
29	A randomized controlled trial of lymphoblastoid interferon- β in patients with chronic hepatitis B lacking HBeAg. <i>Hepatology</i> , 1992, 15, 584-589.	3.6	162
30	SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009, 49, 1821-1827.	3.6	151
31	Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles. <i>Virology</i> , 1989, 173, 522-530.	1.1	145
32	Hepatitis C Virus Infection in Chronic Hepatitis B Virus Carriers. <i>Journal of Infectious Diseases</i> , 1991, 163, 400-402.	1.9	139
33	Prevalence of Liver Disease in a Population of Asymptomatic Persons with Hepatitis C Virus Infection. <i>Annals of Internal Medicine</i> , 2002, 137, 961.	2.0	139
34	Long-term follow-up of anti-HBe-positive chronic active hepatitis B. <i>Hepatology</i> , 1988, 8, 1651-1654.	3.6	138
35	Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. <i>Hepatology</i> , 2000, 31, 1153-1159.	3.6	130
36	Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. <i>Journal of Hepatology</i> , 2018, 69, 345-352.	1.8	128

#	ARTICLE	IF	CITATIONS
37	Hepatitis C Serotype and Response to Interferon Therapy. <i>New England Journal of Medicine</i> , 1994, 330, 143-143.	13.9	126
38	Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. <i>Cancer</i> , 1998, 83, 901-909.	2.0	124
39	Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study. <i>Journal of Hepatology</i> , 2010, 53, 630-638.	1.8	123
40	Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2007, 13, 525.	1.4	123
41	The global health burden of hepatitis C virus infection. <i>Liver International</i> , 2011, 31, 1-3.	1.9	121
42	The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1202-1216.	1.9	111
43	Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C. <i>Journal of Clinical Investigation</i> , 1995, 95, 2067-2075.	3.9	109
44	T lymphocyte sensitization to hbcag and T cell-mediated unresponsiveness to HBsAg in hepatitis B virus-related chronic liver disease. <i>Hepatology</i> , 1985, 5, 192-197.	3.6	102
45	Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C*1. <i>Hepatology</i> , 1995, 22, 700-706.	3.6	102
46	Antibody to Hepatitis C Virus in Post-Transfusion Hepatitis. <i>Annals of Internal Medicine</i> , 1991, 114, 277.	2.0	99
47	Persistent Hepatitis C Viremia Predicts Late Relapse after Sustained Response to Interferon- α in Chronic Hepatitis C. <i>Annals of Internal Medicine</i> , 1996, 124, 1058.	2.0	96
48	Core antigen-specific immunoglobulin G bound to the liver cell membrane in chronic hepatitis B. <i>Gastroenterology</i> , 1982, 82, 218-222.	0.6	94
49	A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. <i>Hepatology</i> , 2009, 50, 1038-1044.	3.6	91
50	Non-organ specific autoantibodies in children with chronic hepatitis C. <i>Journal of Hepatology</i> , 1996, 25, 614-620.	1.8	85
51	Serum and liver HCV RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. <i>Gut</i> , 1998, 42, 856-860.	6.1	81
52	Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. <i>Gut</i> , 2001, 48, 110-115.	6.1	80
53	Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. <i>Journal of Hepatology</i> , 1996, 24, 301-307.	1.8	78
54	Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. <i>Journal of Hepatology</i> , 1996, 24, 517-524.	1.8	76

#	ARTICLE	IF	CITATIONS
55	Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 667-678.	0.8	76
56	T-lymphocyte cytotoxicity to HBsAg-coated target cells in hepatitis B virus infection. <i>Gut</i> , 1977, 18, 1004-1009.	6.1	75
57	An Antibody Which Precipitates Dane Particles in Acute Hepatitis Type B: Relation to Receptor Sites Which Bind Polymerized Human Serum Albumin on Virus Particles. <i>Hepatology</i> , 1984, 4, 220-226.	3.6	75
58	THE ROLE OF HEPATITIS C AND B VIRUS INFECTIONS AS RISK FACTORS FOR SEVERE LIVER COMPLICATIONS FOLLOWING ALLOGENEIC BMT: A PROSPECTIVE STUDY BY THE INFECTIOUS DISEASE WORKING PARTY OF THE EUROPEAN BLOOD AND MARROW TRANSPLANTATION GROUP1. <i>Transplantation</i> , 1999, 68, 1486-1491.	0.5	75
59	Antibody to Hepatitis C Virus and Liver Disease in Volunteer Blood Donors. <i>Annals of Internal Medicine</i> , 1991, 114, 1010.	2.0	72
60	Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia. <i>Journal of Viral Hepatitis</i> , 1998, 5, 179-185.	1.0	72
61	Cloning and Expression of a Novel Hepatitis B Virus-binding Protein from HepG2 Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 36613-36623.	1.6	69
62	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. <i>Journal of Hepatology</i> , 2019, 71, 1106-1115.	1.8	69
63	Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. <i>Hepatology</i> , 1997, 25, 211-215.	3.6	66
64	Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. <i>Bone Marrow Transplantation</i> , 2003, 31, 295-300.	1.3	65
65	Antibodies to hepatitis C virus in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1991, 12, 60-63.	1.8	64
66	Morbidity and Mortality Due to Liver Disease in Children Undergoing Allogeneic Bone Marrow Transplantation: A 10-Year Prospective Study. <i>Blood</i> , 1997, 90, 3799-3805.	0.6	64
67	Fibrosis progression in initially mild chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2006, 13, 297-302.	1.0	64
68	ANTIBODY RESPONSE TO PRE-S2 AND HEPATITIS B VIRUS INDUCED LIVER DAMAGE. <i>Lancet</i> , The, 1988, 331, 1421-1424.	6.3	63
69	Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. <i>Pharmacoeconomics</i> , 2004, 22, 257-265.	1.7	63
70	Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: Potential role of insulin. <i>World Journal of Gastroenterology</i> , 2008, 14, 5695.	1.4	63
71	Genotypes of hepatitis C virus in Italian patients with chronic hepatitis C. <i>International Hepatology Communications</i> , 1994, 2, 105-112.	0.7	62
72	Hepatitis B e antigen negative chronic active hepatitis: hepatitis B virus core mutations occur predominantly in known antigenic determinants. <i>Journal of Viral Hepatitis</i> , 1995, 2, 77-84.	1.0	62

#	ARTICLE	IF	CITATIONS
73	Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 495 patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 1995, 2, 33-38.	1.0	62
74	Therapy of acute hepatitis C. <i>Hepatology</i> , 2002, 36, S195-S200.	3.6	61
75	Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. <i>Gastroenterology</i> , 2000, 119, 1649-1655.	0.6	60
76	Serum levels of soluble CD30 in chronic hepatitis B virus infection. <i>Clinical and Experimental Immunology</i> , 1996, 103, 105-110.	1.1	59
77	Ten year incidence of HCV infection in northern Italy and frequency of spontaneous viral clearance. <i>Gut</i> , 2003, 52, 1030-1034.	6.1	59
78	Autoantibodies during α -interferon therapy for chronic hepatitis B. <i>Journal of Medical Virology</i> , 1991, 34, 132-135.	2.5	57
79	Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2b. <i>Journal of Hepatology</i> , 1994, 20, 416-420.	1.8	57
80	Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon- α . <i>Journal of Viral Hepatitis</i> , 1995, 2, 91-96.	1.0	57
81	Virus replication and liver disease in chronic hepatitis B virus infection. <i>Digestive Diseases and Sciences</i> , 1983, 28, 962-966.	1.1	55
82	Virus-Associated Receptors for Polymerized Human Serum Albumin in Acute and in Chronic Hepatitis B Virus Infection. <i>Gastroenterology</i> , 1983, 84, 220-226.	0.6	55
83	Effect of Retreatment with Interferon Alone or Interferon plus Ribavirin on Hepatitis C Virus Quasispecies Diversification in Nonresponder Patients with Chronic Hepatitis C. <i>Journal of Virology</i> , 1999, 73, 7241-7247.	1.5	55
84	Patterns of antibodies to hepatitis C virus in patients with chronic non-A, non-B hepatitis and their relationship to viral replication and liver disease. <i>Hepatology</i> , 1993, 17, 179-182.	3.6	54
85	Hepatitis B virus precore/core variation and interferon therapy. <i>Hepatology</i> , 1995, 22, 1355-1362.	3.6	54
86	Interferon α and Ribavirin Combination Therapy in Patients With Chronic Hepatitis C and Mixed Cryoglobulinemia. <i>Blood</i> , 1998, 92, 2983-2984.	0.6	54
87	Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. <i>Journal of Viral Hepatitis</i> , 2004, 11, 459-464.	1.0	54
88	Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. <i>Journal of Viral Hepatitis</i> , 2007, 14, 556-563.	1.0	53
89	Differential distribution of hepatitis B core and E antigens in hepatocytes: Analysis by monoclonal antibodies. <i>Hepatology</i> , 1986, 6, 199-204.	3.6	51
90	HEPATITIS C VIRUS INFECTION IN PATIENTS UNDERGOING ALLOGENEIC BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1991, 52, 315-317.	0.5	51

#	ARTICLE	IF	CITATIONS
91	Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2006, 13, 199-205.	1.0	51
92	Changes in Serum Hepatitis B Virus (HBV) DNA Positivity in Chronic HBV Infection: Results of a Long-Term Follow-Up Study of 138 Patients. <i>Journal of Infectious Diseases</i> , 1986, 154, 562-569.	1.9	50
93	Therapy of acute hepatitis C. <i>Hepatology</i> , 2002, 36, s195-s200.	3.6	50
94	Cryptogenic chronic liver disease and hepatitis C virus infection in children. <i>Journal of Hepatology</i> , 1992, 15, 73-76.	1.8	49
95	Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. <i>Journal of Hepatology</i> , 2005, 42, 266-274.	1.8	49
96	Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. <i>Journal of Viral Hepatitis</i> , 2008, 15, 212-218.	1.0	49
97	What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?. <i>Liver International</i> , 2009, 29, 15-18.	1.9	49
98	Hepatitis B virus markers in children with acute leukemia: The effect of chemotherapy. <i>Journal of Medical Virology</i> , 1985, 15, 29-33.	2.5	48
99	Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. <i>Journal of Hepatology</i> , 2006, 44, 83-87.	1.8	48
100	Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis. <i>Antiviral Research</i> , 2001, 52, 199-207.	1.9	47
101	Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 1989, 9, 331-337.	1.8	46
102	Diagnosis of hepatitis C. <i>Journal of Hepatology</i> , 1991, 12, 279-282.	1.8	46
103	Antibodies to hepatitis C virus in community-acquired acute non-A, non-B hepatitis. <i>Journal of Hepatology</i> , 1991, 12, 176-180.	1.8	46
104	Hepatitis C genotypes in patients with dual hepatitis B and C virus infection. <i>Journal of Medical Virology</i> , 1996, 48, 157-160.	2.5	46
105	Natural history of initially mild chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2004, 36, 646-654.	0.4	45
106	Review article: management of patients with chronic hepatitis C virus infection and 'normal' alanine aminotransferase activity. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1133-1149.	1.9	45
107	Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). <i>Nutrition and Metabolism</i> , 2010, 7, 13.	1.3	44
108	PREDICTABILITY BEFORE TRANSPLANT OF HEPATIC COMPLICATIONS FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1989, 48, 68-71.	0.5	43

#	ARTICLE	IF	CITATIONS
109	Chronic Hepatitis B: A Critical Appraisal of Current Approaches to Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 233-248.	2.4	43
110	In vivo translational efficiency of different hepatitis C virus 5'UTRs. <i>FEBS Letters</i> , 1997, 411, 275-280.	1.3	42
111	Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. <i>Liver International</i> , 2011, 31, 4-17.	1.9	42
112	Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfecting with hepatitis D virus. <i>Journal of Viral Hepatitis</i> , 2012, 19, e170-6.	1.0	41
113	Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 92-104.	1.9	41
114	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 658-666.	1.8	41
115	Prevalence and Incidence of Cholecystolithiasis in Cirrhosis and Relation to the Etiology of Liver Disease. <i>Digestion</i> , 1997, 58, 293-298.	1.2	39
116	Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, e212-6.	1.0	39
117	Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction?. <i>Liver International</i> , 2017, 37, 802-808.	1.9	38
118	Chronic hepatitis type B in childhood: longitudinal study of 35 cases. <i>Gut</i> , 1981, 22, 499-504.	6.1	37
119	Significance of anti-HBx antibodies in hepatitis B virus infection. <i>Hepatology</i> , 1991, 13, 143-149.	3.6	37
120	Levamisole therapy in chronic type B hepatitis. <i>Gastroenterology</i> , 1986, 91, 692-696.	0.6	36
121	Hepatitis B virus binds to peripheral blood mononuclear cells via the pre S1 protein. <i>Journal of Hepatology</i> , 1991, 12, 203-206.	1.8	35
122	Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B. <i>Gastroenterology</i> , 1998, 114, 167-172.		34
123	Parenchymal transforming growth factor beta-1: Its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1302-1308.	1.4	34
124	Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life. <i>Digestive and Liver Disease</i> , 2005, 37, 850-860.	0.4	34
125	Long-Term Persistence of Hepatitis B Virus DNA in the Serum of Children with Chronic Hepatitis B after Hepatitis B e Antigen to Antibody Seroconversion. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 1996, 22, 270-274.	0.9	34
126	Analysis of the hepatitis C virus genome in patients with anti-LKM-1 autoantibodies. <i>Journal of Hepatology</i> , 1994, 21, 273-276.	1.8	33

#	ARTICLE	IF	CITATIONS
127	Changes in hepatitis Be antigen/antibody system in children with chronic hepatitis B virus infection. <i>Journal of Pediatrics</i> , 1983, 103, 718-722.	0.9	32
128	Nature and display of hepatitis B virus envelope proteins and the humoral immune response. <i>Seminars in Immunopathology</i> , 1990, 12, 5-23.	4.0	32
129	Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. <i>Liver</i> , 1990, 10, 141-146.	0.1	31
130	Organ-specificity and diagnostic value of cell-mediated immunity against a liver-specific membrane protein: Studies in hepatic and non-hepatic diseases. <i>Klinische Wochenschrift</i> , 1975, 53, 1061-1067.	0.6	30
131	Latent hepatitis B virus infection in childhood hepatocellular carcinoma analysis by polymerase chain reaction. <i>Cancer</i> , 1992, 69, 2731-2735.	2.0	30
132	Chronic hepatitis C: Interferon retreatment of relapsers. A meta-analysis of individual patient data. <i>Hepatology</i> , 1999, 30, 801-807.	3.6	30
133	The pattern of response to interferon alpha ($\hat{I}\pm$ -IFN) predicts sustained response to a 6-month $\hat{I}\pm$ -IFN and ribavirin retreatment for chronic hepatitis C. <i>Journal of Hepatology</i> , 2000, 33, 128-134.	1.8	30
134	Proapoptotic effect of hepatitis C virus CORE protein in transiently transfected cells is enhanced by nuclear localization and is dependent on PKR activation. <i>Journal of Hepatology</i> , 2004, 40, 77-85.	1.8	30
135	Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa $\hat{E}2$ A interferon. <i>Liver</i> , 1994, 14, 257-264.	0.1	30
136	Hyperinsulinaemia reduces the 24-h virological response to PEG-interferon therapy in patients with chronic hepatitis C and insulin resistance. <i>Journal of Viral Hepatitis</i> , 2009, 17, 475-80.	1.0	30
137	Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. <i>Epidemics</i> , 2021, 34, 100442.	1.5	30
138	Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011, 43, 259-265.	0.4	29
139	Changes in hepatitis B virus DNA-polymerase activity in patients with chronic infection. <i>Journal of Medical Virology</i> , 1981, 8, 223-229.	2.5	28
140	Therapy for chronic hepatitis B with lymphoblastoid interferon- $\hat{I}\pm$ and levamisole. <i>Hepatology</i> , 1992, 16, 1115-1119.	3.6	28
141	Risk factors and prevention of hepatocellular carcinoma in HCV infection. <i>Digestive Diseases and Sciences</i> , 1996, 41, 49S-55S.	1.1	28
142	Acute and chronic hepatitis in childhood leukemia: A multicentric study from the italian pediatric cooperative group for therapy of acute leukemia (AIL-AIEOP). <i>Medical and Pediatric Oncology</i> , 1985, 13, 203-206.	1.0	27
143	Microsomal triglyceride transfer protein polymorphism ($\hat{a}^{\sim}493G/T$) is associated with hepatic steatosis in patients with chronic hepatitis C. <i>Liver International</i> , 2009, 29, 557-565.	1.9	27
144	Fine specificity of human antibody response to the pres1 domain of hepatitis B virus. <i>Hepatology</i> , 1990, 12, 199-203.	3.6	26

#	ARTICLE	IF	CITATIONS
145	A 385 insertion in the hypervariable region 1 of hepatitis C virus E2 envelope protein is found in some patients with mixed cryoglobulinemia type 2. <i>Blood</i> , 2001, 98, 2657-2663.	0.6	26
146	Development of a simple HPLC-UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 121, 197-203.	1.4	26
147	Ultrastructural changes in the liver of patients with chronic non-A, non-B hepatitis. <i>Journal of Medical Virology</i> , 1981, 7, 205-212.	2.5	25
148	Effect of Recombinant or Lymphoblastoid Interferon- α on Alanine Aminotransferase in Patients with Chronic Hepatitis C or Chronic Non-A Non-B Hepatitis. <i>Clinical Drug Investigation</i> , 1995, 9, 239-254.	1.1	25
149	Human immunodeficiency virus infection and hepatitis C pathology. <i>Liver</i> , 1994, 14, 314-319.	0.1	25
150	Modeling cost-effectiveness and health gains of a universal versus prioritized hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017, 66, 1814-1825.	3.6	25
151	Relationship between HBcAg in serum and liver and HBV replication in patients with HBsAg-positive chronic liver disease. <i>Journal of Medical Virology</i> , 1985, 17, 145-152.	2.5	24
152	Hepatitis C virus genotypes and severity of chronic liver disease in haemophiliacs. <i>British Journal of Haematology</i> , 1995, 91, 708-713.	1.2	24
153	Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon- α . <i>Journal of Viral Hepatitis</i> , 1999, 6, 367-372.	1.0	24
154	Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. <i>Antiviral Research</i> , 2012, 96, 422-429.	1.9	24
155	Changes in hepatitis B virus DNA polymerase in relation to the outcome of acute hepatitis type B. <i>Gut</i> , 1979, 20, 190-195.	6.1	23
156	Serum levels of soluble interleukin-2 receptors in acute and chronic viral hepatitis. <i>Digestive Diseases and Sciences</i> , 1989, 34, 1559-1563.	1.1	23
157	Literature review of the distribution of hepatitis C virus genotypes across Europe. <i>Journal of Medical Virology</i> , 2016, 88, 2157-2169.	2.5	23
158	Comparison of genotyping and serotyping methods for the identification of hepatitis C virus types. <i>Journal of Virological Methods</i> , 1995, 55, 303-307.	1.0	22
159	Comparison of serum and liver hepatitis C virus quasispecies in HCV-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 1998, 29, 887-892.	1.8	22
160	Impact of a sustained virological response on the long-term outcome of hepatitis C. <i>Liver International</i> , 2011, 31, 18-22.	1.9	22
161	<i>In vivo</i> molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. <i>Ecological Management and Restoration</i> , 2015, 28, 394-403.	0.2	22
162	Receptors for polymerized human serum albumin on hepatitis B virus particles detected by radioimmunoassay: Changes in receptor activity in serum during acute and chronic infection. <i>Journal of Virological Methods</i> , 1983, 6, 151-159.	1.0	21

#	ARTICLE	IF	CITATIONS
163	Detection of hepatitis B virus DNA sequences in bone marrow of children with leukemia. <i>Cancer</i> , 1987, 59, 292-296.	2.0	21
164	Antibody to the hepatitis B virus receptor for polymerized albumin in acute infection and in hepatitis B vaccine recipients. <i>Journal of Hepatology</i> , 1986, 3, 393-398.	1.8	20
165	Detection by immunofluorescence of an antigen-antibody system in patients with acute and chronic non-A, non-B hepatitis. <i>Liver</i> , 1981, 1, 183-190.	0.1	20
166	Anti-LSP antibodies in acute liver disease.. <i>Gut</i> , 1982, 23, 603-607.	6.1	19
167	Chronic evolution of acute hepatitis type B: Prevalence and predictive markers. <i>Infection</i> , 1986, 14, 64-67.	2.3	19
168	Hepatitis C Virus Serum Markers and Liver Disease in Children with Leukemia. <i>Leukemia and Lymphoma</i> , 1995, 17, 245-249.	0.6	19
169	Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. <i>Journal of Viral Hepatitis</i> , 2000, 7, 203-210.	1.0	19
170	Prognostic value of hepatitis B core antigen (HBcAg) expression in the liver of children with chronic hepatitis type B. <i>Liver</i> , 1985, 5, 40-47.	0.1	19
171	Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: A vicious circle of clinical significance?. <i>Hepatology</i> , 2011, 54, 484-494.	3.6	19
172	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017, 49, 731-741.	0.4	19
173	HBV therapy: Guidelines and open issues. <i>Digestive and Liver Disease</i> , 2011, 43, S57-S63.	0.4	18
174	Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial. <i>Journal of Viral Hepatitis</i> , 2015, 22, 596-606.	1.0	18
175	Barriers to effective management of hepatitis C virus in people who inject drugs: Evidence from outpatient clinics. <i>Drug and Alcohol Review</i> , 2019, 38, 644-655.	1.1	18
176	Do single nucleotide mutations result in clinically significant changes in hepatitis B virus pathogenicity?. <i>Journal of Hepatology</i> , 1990, 10, 268-270.	1.8	17
177	Recent progress and new trends in the treatment of hepatitis B. <i>Journal of Medical Virology</i> , 2002, 67, 458-462.	2.5	17
178	Impact of NS5A Sequences of Hepatitis C Virus Genotype 1a on Early Viral Kinetics during Treatment with Peginterferon-2a plus Ribavirin. <i>Journal of Infectious Diseases</i> , 2007, 196, 998-1005.	1.9	17
179	HBV DNA sequences are rarely detected in the liver of patients with HBsAg-negative chronic active liver disease and with hepatocellular carcinoma in Italy. <i>Liver</i> , 1987, 7, 211-215.	0.1	17
180	Hepatitis C virus genotypes and liver disease in patients undergoing allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1997, 19, 237-240.	1.3	16

#	ARTICLE	IF	CITATIONS
181	High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. <i>Journal of Hepatology</i> , 2001, 34, 723-729.	1.8	16
182	Prevalence of wild-type in NS5A-PKR protein kinase binding domain in HCV-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2002, 36, 116-122.	1.8	16
183	Expression of preS1 and preS2 in the liver of chronic hepatitis B virus carriers. <i>Journal of Hepatology</i> , 1988, 7, 157-163.	1.8	15
184	Interferon therapy for the anti-HBe positive form of chronic hepatitis B. <i>Antiviral Research</i> , 1994, 24, 145-153.	1.9	15
185	Detailed analysis of the E2-IgM complex in hepatitis C-related type II mixed cryoglobulinaemia. <i>Journal of Viral Hepatitis</i> , 2006, 13, 166-176.	1.0	15
186	Evolution of Hepatitis C Virus Quasispecies in Children with Chronic Hepatitis C. <i>Infection</i> , 2006, 34, 62-65.	2.3	15
187	Heterogeneity of CK2 phosphorylation sites in the NS5A protein of different hepatitis C virus genotypes. <i>Journal of Hepatology</i> , 2007, 47, 768-776.	1.8	15
188	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
189	Outcome of Acute Hepatitis C and Role of Alpha Interferon Therapy. , 1994, , 604-606.		15
190	Interferon $\hat{2}$ -1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2005, 11, 4484.	1.4	15
191	HBAg ON LIVER-CELL SURFACE IN VIRAL HEPATITIS. <i>Lancet, The</i> , 1975, 305, 346.	6.3	14
192	Long-term evolution of chronic hepatitis B in children with antibody to hepatitis B e antigen. <i>Journal of Pediatrics</i> , 1990, 116, 552-555.	0.9	14
193	Antibody to hepatitis C virus in cryptogenic chronic liver disease. <i>Journal of Medical Virology</i> , 1991, 35, 151-154.	2.5	14
194	Selection of a precore mutant of hepatitis B virus and reactivation of chronic hepatitis B acquired in childhood. <i>Journal of Pediatrics</i> , 1993, 123, 583-585.	0.9	14
195	Optimizing PEG-interferon and ribavirin combination therapy for patients infected with HCV-2 or HCV-3: is the puzzle completed?. <i>Journal of Hepatology</i> , 2004, 40, 1032-1035.	1.8	14
196	Serum Hepatitis B Virus DNA in Acute Hepatitis Type B. <i>Digestion</i> , 1986, 34, 46-50.	1.2	13
197	A randomized controlled trial of thymopentin therapy in patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 1994, 21, 361-366.	1.8	13
198	Patterns of antibodies to hepatitis C virus and hepatitis C virus replication in children with chronic non-A, non-B hepatitis. <i>Journal of Pediatrics</i> , 1994, 125, 916-918.	0.9	13

#	ARTICLE	IF	CITATIONS
199	Detection of fluorescent organic nanoparticles by confocal laser endomicroscopy in a rat model of Barrett’s esophageal adenocarcinoma. International Journal of Nanomedicine, 2015, 10, 6811.	3.3	13
200	From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease, 2016, 48, 995-1005.	0.4	13
201	Adherence to WCRF/AICR lifestyle recommendations for cancer prevention and the risk of Barrett&TM's esophagus onset and evolution to esophageal adenocarcinoma: results from a pilot study in a high-risk population. European Journal of Nutrition, 2016, 55, 1563-1571.	1.8	13
202	Hyperinsulinemia Promotes Esophageal Cancer Development in a Surgically-Induced Duodeno-Esophageal Reflux Murine Model. International Journal of Molecular Sciences, 2018, 19, 1198.	1.8	13
203	Polyalbumin receptors on hepatitis B virus and on 22 nm hepatitis B surface antigen (H BsAg)2 particles. Journal of Medical Virology, 1984, 13, 355-360.	2.5	12
204	Different mechanisms responsible for in vitro cell-mediated cytotoxicity to autologous hepatocytes in children with autoimmune and HbsAg-positive chronic liver disease. Journal of Pediatrics, 1985, 106, 899-906.	0.9	12
205	Hepatitis B virus (HBV)-DNA-positive hepatocellular carcinoma following hepatitis B virus infection in a child. Journal of Medical Virology, 1987, 23, 151-155.	2.5	12
206	Hepatitis C virus infection associated with human hepatocellular carcinoma. Cancer, 1998, 83, 1489-1494.	2.0	12
207	Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B?. Hepatology, 2003, 38, 18-20.	3.6	12
208	Radioimmunoassay for Hepatitis B éAntigen and Antibody: Correlations with Viral Replication and Prognostic Value. Vox Sanguinis, 1981, 41, 139-145.	0.7	11
209	Virus receptors for polymerized human albumin: A prognostic marker in HBeAg-positive chronic hepatitis type B?. Journal of Medical Virology, 1982, 10, 141-146.	2.5	11
210	Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2007, 14, 070901052026003-???	1.0	11
211	Who is more likely to respond to dual treatment with pegylated&interferon and ribavirin for chronic hepatitis C? A genderéoriented analysis. Journal of Viral Hepatitis, 2013, 20, 790-800.	1.0	11
212	Protease inhibitorsébased therapy induces acquired spherocyticélike anaemia and ineffective erythropoiesis in chronic hepatitis C virus patients. Liver International, 2016, 36, 49-58.	1.9	11
213	Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. Journal of Viral Hepatitis, 1999, 6, 321-327.	1.0	10
214	Interferon Alfacon-1. BioDrugs, 1999, 12, 343-357.	2.2	10
215	Non-invasive markers of liver fibrosis: How to use them in clinical practice?. Journal of Hepatology, 2007, 46, 529-530.	1.8	10
216	Hepatitis C virus serotypes and liver pathology. Liver, 1996, 16, 353-357.	0.1	10

#	ARTICLE	IF	CITATIONS
217	Virological Changes in Chronic Hepatitis Type B Treated with Levamisole. <i>Digestion</i> , 1982, 25, 131-137.	1.2	9
218	Cryptogenic Chronic Liver Disease and Serum or Liver Hepatitis B Virus Markers. <i>Digestion</i> , 1988, 39, 251-256.	1.2	9
219	Cytokeratins patterns in childhood primary liver tumors. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 225-227.	1.0	9
220	Pilot study on the efficacy of intravenous natural γ -interferon therapy in Italian patients with chronic hepatitis C and relation to the HCV genotype. <i>International Hepatology Communications</i> , 1995, 3, 237-243.	0.7	9
221	Hepatitis C virus genotypes in chronic hepatitis C of children. <i>Journal of Viral Hepatitis</i> , 1996, 3, 323-327.	1.0	9
222	Treatment of chronic hepatitis C with interferon α by monitoring the response according to viraemia. <i>Journal of Viral Hepatitis</i> , 1997, 4, 107-112.	1.0	9
223	Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy. <i>Journal of Clinical Virology</i> , 2011, 50, 217-220.	1.6	9
224	The dilemma for patients with chronic hepatitis C: Treat now or warehouse?. <i>Digestive and Liver Disease</i> , 2014, 46, 27-29.	0.4	9
225	Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2014, 46, 18-24.	0.4	9
226	Cost-effectiveness analysis of the use of daclatasvir+sofosbuvir+sofosbuvir+sofosbuvir (16weeks and 12weeks) vs sofosbuvir+sofosbuvir (16weeks and 24weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. <i>European Journal of Health Economics</i> , 2018, 19, 37-44.	1.4	9
227	Pkr Gene Expression and Response to Pegylated Interferon plus Ribavirin Therapy in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2004, 9, 763-770.	0.6	9
228	A 7 year survey of acute hepatitis type B.. <i>Archives of Disease in Childhood</i> , 1983, 58, 993-996.	1.0	8
229	PRE-S2 ANTIBODIES IN HEPATITIS B. <i>Lancet</i> , The, 1986, 328, 1457-1458.	6.3	8
230	IgM antibody to hepatitis B core antigen in children with chronic type B hepatitis. <i>European Journal of Pediatrics</i> , 1987, 146, 394-397.	1.3	8
231	Lymphoproliferative disease of granular lymphocytes in a patient with concomitant hepatitis B virus infection of CD4 lymphocytes. <i>Journal of Clinical Immunology</i> , 1989, 9, 401-408.	2.0	8
232	Transcatheter arterial embolisation versus no treatment in cirrhotic patients with hepatocellular carcinoma: a retrospective comparative study. <i>European Radiology</i> , 1994, 4, 155.	2.3	8
233	The evolution of the therapeutic strategy in hepatitis C: Features of sofosbuvir and indications. <i>Digestive and Liver Disease</i> , 2014, 46, S174-S178.	0.4	8
234	Insulin promotes HER2 signaling activation during Barrett's Esophagus carcinogenesis. <i>Digestive and Liver Disease</i> , 2017, 49, 630-638.	0.4	8

#	ARTICLE	IF	CITATIONS
235	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128.	2.0	8
236	Cell-Mediated Immunity to HBcAg in Chronic HBV Infection. <i>American Journal of Clinical Pathology</i> , 1987, 88, 494-498.	0.4	7
237	Antibody to pre-S antigens in hepatitis B virus infection. <i>Hepatology</i> , 1987, 7, 207-208.	3.6	7
238	Evidence Against the Role of Hepatitis C Virus in Severe Liver Damage Occurring Early in the Course of Acute Leukemia in Children. <i>Leukemia and Lymphoma</i> , 1994, 13, 119-122.	0.6	7
239	Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies. , 2000, 60, 133-138.		7
240	A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions. <i>BMC Infectious Diseases</i> , 2022, 22, 58.	1.3	7
241	Hepatitis B core antigen (HBcAg) in serum of patients with chronic hepatitis B detected by a modified radioimmunoassay. <i>Journal of Medical Virology</i> , 1985, 17, 51-56.	2.5	6
242	Methods for the study of pre-S proteins of hepatitis B virus and their antibodies: pathogenetic and clinical implications. <i>Research in Clinic and Laboratory</i> , 1988, 18, 241-258.	0.3	6
243	Hepatitis B virus DNA forms in the liver of chronically infected individuals. <i>Journal of Hepatology</i> , 1989, 9, 29-35.	1.8	6
244	The role of PreS1 in the interaction of hepatitis B virus with human hepatocytes. <i>Hepatology</i> , 1991, 14, 405-406.	3.6	6
245	Hepatitis C virus quasispecies in the natural course of HCV-related disease in patients with haemophilia. <i>Haemophilia</i> , 2004, 10, 81-86.	1.0	6
246	Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. <i>Scientific Reports</i> , 2019, 9, 585.	1.6	6
247	Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 190-200.	0.7	6
248	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021, 53, 612-619.	0.4	6
249	Recombinant interferon-alfa therapy in children with chronic hepatitis C. <i>Hepatology</i> , 1995, 22, 1623-1627.	3.6	6
250	Does Hepatitis B Virus Cross the Bloodâ€‘Brain Barrier?. <i>New England Journal of Medicine</i> , 1986, 314, 518-519.	13.9	5
251	Pattern of Liver Disease Following High-Dose Cytosine Arabinoside (HDARAC) Therapy in Children with Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1990, 2, 229-233.	0.6	5
252	Polymerase-chain-reaction-based semi-quantification of hepatitis D viraemia in patients treated with high doses of Î±2b interferon. <i>Research in Virology</i> , 1994, 145, 287-295.	0.7	5

#	ARTICLE	IF	CITATIONS
253	Human leucocyte interferon-alpha in the treatment of chronic hepatitis C. Digestive and Liver Disease, 2001, 33, 347-352.	0.4	5
254	Implementing non-invasive markers for liver fibrosis in clinical practice. Journal of Hepatology, 2008, 48, 880-881.	1.8	5
255	In vitro effect of lymphoblastoid $\hat{\iota}$ -interferon on subpopulations of effector cells mediating cytotoxicity for autologous hepatocytes in hepatitis B and non-A, non-B. International Journal of Immunopharmacology, 1986, 8, 887-891.	1.1	4
256	Reverse transcriptase activity in post-transfusion non-A, non-B hepatitis: I. Characterisation and association with retrovirus-like particles in serum. Serodiagnosis and Immunotherapy in Infectious Disease, 1987, 1, 339-346.	0.2	4
257	Serum HBV-DNA in anti-HBe positive patients detected by filter and liquid phase hybridization assays. Molecular and Cellular Probes, 1989, 3, 245-249.	0.9	4
258	Specificity and patterns of antibodies to hepatitis C virus in hepatocellular carcinoma. Hepatology, 1991, 14, 959-959.	3.6	4
259	Anti-interferon antibodies during interferon therapy for chronic hepatitis C. Journal of Hepatology, 1994, 21, 135.	1.8	4
260	Hepatitis C serotypes in chronic hepatitis C of children. International Hepatology Communications, 1995, 4, 35-41.	0.7	4
261	HBeAg and anti-HBe in chronic hepatitis B virus infection. Gastroenterology, 1981, 80, 881-882.	0.6	3
262	IgM antibodies to hepatitis C virus. Journal of Viral Hepatitis, 1994, 1, 85-86.	1.0	3
263	Hepatitis B virus precore/core variation and interferon therapy*1. Hepatology, 1995, 22, 1355-1362.	3.6	3
264	Meta-Analysis. Clinical Drug Investigation, 1995, 10, 188-190.	1.1	3
265	Characteristics of hepatitis C virus before and after interferon treatment in patients with ongoing viraemia but sustained biochemical response. , 1998, 54, 7-11.		3
266	Hepatitis B and Hepatitis C Virus Infections in Stem Cell Transplantation. Leukemia and Lymphoma, 1999, 35, 255-260.	0.6	3
267	Clinical trial: comparison of weekly once versus twice half-dose weekly administration of pegylated interferon alpha 2b in combination with ribavirin for the treatment of HCV $\hat{\iota}$ positive patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2007, 26, 1077-1082.	1.9	3
268	Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection. European Journal of Gastroenterology and Hepatology, 2013, 25, 1385-1395.	0.8	3
269	Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 376-377.	0.8	3
270	$\hat{\iota}$ -Interferon enhances non-T cell cytotoxicity for autologous hepatocytes in acute and chronic HBV infection. Journal of Hepatology, 1986, 3, S279-S281.	1.8	2

#	ARTICLE	IF	CITATIONS
271	Reverse transcriptase activity in post-transfusion non-A, non-B hepatitis: II. Relation to liver disease activity and long-term outcome. <i>Serodiagnosis and Immunotherapy in Infectious Disease</i> , 1987, 1, 347-352.	0.2	2
272	A model to predict long-term sustained response to interferon therapy in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 1997, 4, 193-197.	1.0	2
273	Natural history of chronic hepatitis B. <i>Current Hepatitis Reports</i> , 2004, 3, 54-60.	0.3	2
274	Space-occupying lesions of the liver detected by ultrasonography and their relation to hepatocellular carcinoma in cirrhosis. <i>Liver</i> , 1992, 12, 80-83.	0.1	2
275	Interpreting liver stiffness in the cirrhotic range: What are we measuring?. <i>Journal of Hepatology</i> , 2009, 50, 424-425.	1.8	2
276	Monoclonal Radioimmunoassay for Hepatitis B Surface Antigen in Sera of Children With Acute Leukemia. <i>Journal of Medical Virology</i> , 1986, 20, 101-104.	2.5	1
277	Corrigendum to "SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS" [Hepatology 42 (2005) 615-624]. <i>Journal of Hepatology</i> , 2005, 43, 1098.	1.8	1
278	Hepatitis B virus type 2 in Italian hemophiliacs. <i>Transfusion</i> , 1989, 29, 558-559.	0.8	1
279	Interferon and Ribavirin Combination Therapy in Patients With Chronic Hepatitis C and Mixed Cryoglobulinemia. <i>Blood</i> , 1998, 92, 2983-2984.	0.6	1
280	Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection. <i>Annals of Gastroenterology</i> , 2017, 30, 534-541.	0.4	1
281	Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus. <i>European Review for Medical and Pharmacological Sciences</i> , 2018, 22, 7024-7033.	0.5	1
282	Circulating hepatocyte membrane-specific autoantibodies in chronic active hepatitis type B. <i>Digestive Diseases and Sciences</i> , 1984, 29, 620-624.	1.1	0
283	From Bench to Bedside. <i>Journal of Hepatology</i> , 2005, 42, 301.	1.8	0
284	Analysis of immunoglobulin variable kappa gene mutations in cutaneous B-cell lymphoma. <i>Journal of Dermatological Science</i> , 2007, 47, 248-252.	1.0	0
285	Immunofluorescence tests in non-A, non-B hepatitis. <i>Liver</i> , 1982, 2, 244-244.	0.1	0
286	Reply:. <i>Hepatology</i> , 2009, 50, 657-657.	3.6	0
287	Non-invasive algorithms for liver fibrosis: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 311-313.	1.9	0
288	Diagnostic algorithms for liver fibrosis in hepatitis C: Are they ready to avoid liver biopsy?. <i>Hepatology</i> , 2012, 55, 652-653.	3.6	0

#	ARTICLE	IF	CITATIONS
289	Impact if HBV infection in HCV/HBV coinfectd patients treated with DAAs in north Italy. Journal of Hepatology, 2020, 73, S595-S596.	1.8	0
290	Management of HCV-2 and HCV-3 Non-Responders and Relapsers. , 0, , 43-46.		0